Retina/Vitreous News

Providers can use continuous glucose monitoring metrics as well as HbA1c to assess diabetic retinopathy risk for adults with type 1 diabetes, according to findings published in Diabetes Technology & Therapeutics.

The top Healio blogs in ophthalmology last year explored the future of drug prices in the wake of the Inflation Reduction Act and important tips for avoiding Stark Law violations.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Bart Leroy, MD, PhD, speaks about RNA interference technology for the treatment of Leber congenital amaurosis type 10.

K2 Medical Research has partnered with Magruder Eye Institute and RetiSpec in a research pilot to improve access to clinical trials, using AI-driven technology to prescreen eligible candidates in an eye care setting.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Quan Dong Nguyen, MD, MSc, shares the latest achievements in two areas: intermediate age-related macular degeneration and Stargardt disease.

Among the newer diagnostics used to quantify diabetic retinal disease, the level of evidence is highest for spectral-domain OCT, suggesting its potential role in an updated classification scheme, according to a literature review.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Gemmy Cheung, MD, explains how the definition of pachychoroid is evolving with new understanding from imaging studies.

ROME — There are conflicts in the literature concerning the association of Ozempic, with increased risk or worsening of diabetic retinopathy.

Alimera Sciences has completed enrollment for its Synchronicity study, a prospective, open-label trial to evaluate the safety and efficacy of Yutiq for chronic noninfectious uveitis and related inflammation.

LumiThera submitted a de novo request to the FDA to reclassify the Valeda light delivery system as a Class II device for the treatment of dry age-related macular degeneration, according to a press release.